The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan, MD, Harvard Medical School, Boston, MA, comments on the impact of treatment with a dendritic cell fusion vaccine following autologous transplantation in comparison to autologous transplantation followed by lenalidomide maintenance in patients with multiple myeloma, and discusses how these vaccines may impact T-cell response and clinical outcomes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
